Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer

Australasian Radiology

Volumn 47, Issue 4, 2003, Pages 422-427

  Kneebone, Andrew ^a,c   Turner, Sandra ^a   Berry, Martin ^a   Cakir, Burcu ^a   Gebski, Val ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSURIA; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; MUSCLE CRAMP; NECROSIS; PERFORATION; PETECHIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; STANDARDIZATION; TELANGIECTASIA;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0347722511     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1673.2003.01213.x     Document Type: Article

References (20)

1. Coates M, McCredie M, Taylor R. Cancer in New South Wales: Incidence and Mortality. New South Wales Cancer Council, Sydney, 1992.
2. Hanks GE. External beam radiation treatment for prostate cancer: still the right gold standard. Oncology 1990; 6: 79-86.
3. Perez CA, Hanks GE, Leibel SA, Zietman AG, Fuks Z, Lee WR. Localised carcinoma of the prostate (Stages T1b, T1c, T2 and T3). Review of management with external beam therapy. Cancer 1993; 72: 3156-73.
4. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997; 337: 295-300.
5. Zelefsky MJ, Fuks Z, Happersett L et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241-9.
6. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-11.
7. Pollack A, Smith LG, von Eschenbach AC. External beam radio-therapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000; 48: 507-12.
8. Hanks GE, Hanlon AL, Schultheiss TE et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41: 501-10.
9. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
10. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland [see comments]. Int J Radiat Oncol Biol Phys 2000; 46: 575-80.
11. Willoughby TR, Weinhous MS, Kupelian PA. Daily transabdominal ultrasound localization of the prostate gland with the bat system: 2705 alignments from 100 patients. Int J Radiat Oncol Biol Phys 2000; 48: 308.
12. Mameghan H, Fisher R, Mameghan J, Brook S. Results of external beam radiotherapy in 448 patients with clinically localized adenocarcinoma of the prostate. Aust NZ J Surg 1994; 64: 389-94.
13. Hermanek P, Sobin LH (eds). UICC TNM Classification of Malignant Tumours, 4th edn. Springer-Verlag, Berlin, 1992.
14. American Society for Therapeutic Radiology and Oncology. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41.
15. Zagars GZ, Pollack A, Eschenback AC. Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 33: 23-35.
16. Lee RW, Hanks GEF, Schultheiss TE, Corn BW, Hunt MA. Localised prostate cancer treated by external beam radiotherapy alone - Serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995; 13: 464-9.
17. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
18. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 713-25.
19. Schultheiss TF, Lee RW, Hunt MA, Hanlon AL, Peter RS, Harks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 3-11.
20. Lawton CA, Won M, Pilepich MV et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 935-9.